Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

What Was Tested

The paper reports a study of Insulin Glargine, published as a randomized controlled trial.

This study compared two treatment algorithms for insulin glargine initiation and titration: algorithm 1 (investigator led) versus algorithm 2 (performed by study subjects).

Who Took Part

According to the abstract, 2 subjects were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

A prospective, multicenter (n = 611), multinational (n = 59), open-label, 24-week randomized trial in 4,961 (algorithm 1, n = 2,493; algorithm 2, n = 2,468) suboptimally controlled type 2 diabetic subjects.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

The subjects were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.

Being open-label, the Insulin Glargine study did not mask who received what.

More than one site took part, so the subjects came from several places.

What Was Measured

Topics PubMed links to this paper include Algorithms, Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin and Insulin Glargine.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Glargine in 2 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (Diabetes care), a journal based in United States.

More context: the Insulin Glargine compound page.